1. Products
  2. Vaccines
  3. Prestige® 5 + WNV
View Product label
Vaccine
Prestige® 5 + WNV
New Flu Strains
Indications

This product has been shown effective for the vaccination of healthy horses 6 months of age or older against Eastern and Western encephalomyelitis (EEE and WEE) viruses, equine influenza virus (EIV), equine herpesvirus type 1 (EHV-1), equine herpesvirus type 4 (EHV-4), tetanus and West Nile Virus. Duration of immunity has been shown at 6 months for EIV. Duration of immunity for Eastern and Western encephalomyelitis viruses, EHV-1, EHV-4, tetanus and West Nile Virus has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov. This product has been shown to be effective against virus shedding of EIV, EHV-1 and EHV-4, and encephalitis and viremia caused by West Nile Virus.

Purpose
Science
Administration

The Science of Advanced

  • Multiple antigen combination reduces need for several injections
  • Formulated to minimize reactions and maximize protection
  • Available in 10-dose vials and 1 mL single-dose prefilled syringes
  • West Nile virus (WNV) is the leading cause of arbovirus encephalitis in horses and humans in the United States
  • Tetanus, WNV, EEE and WEE are considered core vaccinations recommended by the AAEP vaccine guidelines and are indicated in the immunization program for all horses each year.
  • Provides 6 months of protection against EIV
  • A combination of inactivated, concentrated, adjuvanted, tissue culture origin equine encephalomyelitis viruses (Eastern and Western), equine herpesvirus types 1 and 4 (EHV-1 and EHV-4), equine influenza virus type H3N8 strains EIV A/eq/Florida/RW/13, EIV A/Equine 2/Kentucky/02 American, EIV A/eq/Richmond/1/07, West Nile virus ‐ flavivirus chimera and tetanus toxoid.
  • Advanced filtration process through the Antigen Purification System (APS™)

The Science of Significant


Updated equine influenza vaccines from Merck Animal Health

Learn More

Science

Gold Standard Challenge Study

In the immunogenicity intrathecal challenge study, the West Nile virus fraction of the Prestige 5 + WNV, Prestige 3 + WNV and Prestige WNV vaccines demonstrated a statistically significant reduction for the following parameters in vaccinates as compared to controls1:

1. Data on file, Merck Animal Health.

Additional Resources

Administration

Dose:

For primary vaccination aseptically administer 1 mL intramuscularly, repeat with a single dose in 3 - 4 weeks. Historically, annual revaccination with this product has been recommended. The need for this booster has not been established. The presence of maternal antibody is known to interfere with the development of active immunity in foals and additional boosters will be required in most young animals. For more information on revaccination frequency, consult your veterinarian.